NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters Option to Purchase Additional Shares
December 13, 2024 17:16 ET | Source: NewAmsterdam Pharma N.V. NAARDEN, The…
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters Option to Purchase Additional Shares
December 13, 2024 17:16 ET | Source: NewAmsterdam Pharma N.V. NAARDEN, The…
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters Option to Purchase Additional Shares
December 13, 2024 17:16 ET | Source: NewAmsterdam Pharma N.V. NAARDEN, The…
NEXTCHEM (MAIRE) AWARDED BY DG FUELS AN EARLY ENGINEERING, LICENSING AND PDP CONTRACT BASED ON ITS PROPRIETARY NX CIRCULAR GASIFICATION TECHNOLOGY FOR AN ADDITIONAL SUSTAINABLE AVIATION FUEL (SAF) PLANT IN NEBRASKA (USA)
Licensing and PDP are subject to Notice to ProceedThis is NEXTCHEM's second…
Nova Leap Health Corp. enters into Term Sheet to amend itsCredit Agreement for up to an Additional $7 millionto Support Continued Growth
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.…
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated…
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
November 12, 2024 16:30 ET | Source: Psyence Biomedical Ltd. NEW YORK,…